PET radiopharm reg reverses FDA policy on nuclear pharmacy, medical groups maintain.
This article was originally published in The Gray Sheet
Executive SummaryPET RADIOPHARMACEUTICAL REG "UNJUSTIFIABLY" REVERSES FDA POLICY, ASHP (the American Society of Health-system Pharmacists), the American Pharmaceutical Association and the American College of Nuclear Physicians/Society of Nuclear Medicine maintain in a July 27 joint letter to FDA Commissioner Kessler. The coalition wrote to express its "profound concern regarding the direction the FDA is taking in regulating PET (positron emission tomography) radiopharmaceuticals" as articulated in the agency's proposed reg on PET products.
You may also be interested in...
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.
Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales of around €120m.